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Despite the development of percutaneous coronary interven-
ion (PCI), left ventricular (LV) remodeling after acute myocardial
nfarction (AMI) is a serious complication that causes cardiac
hrombosis, heart failure, and ventricular arrhythmia, leading to
n unfavorable clinical outcome. The size of infarction determined
ithin several hours after the attack is the most critical determinant
f subsequent LV remodeling [1].  PCI has reduced the mortality of
MI, however, the incidence of heart failure is increasing and has
ecome a serious problem in recent years [2].  Mechanical factors,
edical interventions, and humoral factors such as vasoactive sub-
tances and cytokines have been reported to be associated with LV
emodeling in the chronic phase after AMI  [3,4]. In particular, apop-
otic cell death in infarcted tissue is reported to play an important
ole in progression of LV remodeling after AMI  [5].  Hayakawa et al.
ave reported that inhibition of granulation tissue cell apoptosis by
 pancaspase inhibitor signiﬁcantly improved LV remodeling and
eart failure in the chronic stage after AMI  [6].
Immune cells can initiate apoptosis of target cells through vari-
us stimulations including tumor necrosis factor  (TNF), Fas/Fas
igand (FasL), granzymes, anti-cancer drugs, and oxidative stress
7]. As shown in Fig. 1, several mechanisms are involved in ini-
iation of apoptosis. To date two major pathways are known for
nduction of apoptosis: extrinsic pathway and intrinsic pathway.
eath ligands and receptors induce the extrinsic pathway, whereas
itochondrial cytochrome C is a major signaling molecule in the
ntrinsic pathway. In both pathways, cascade reaction of caspases is
ecessary. Kondo et al. showed the signiﬁcant association between
lasma granzyme B level and the extent of LV remodeling with AMI
8]. Soeki et al. have reported increased FasL levels in patients with
V remodeling 2–3 weeks after AMI  [9].  The number of patients
as small in these two studies. The role of TNF in heart fail-
re has been studied enthusiastically in animal models as well
s human studies [10]. TNF has been reported to alter spatial
lignment of cardiac myocytes in LV wall by reducing the colla-
en cross-linking. Upregulation of matrix metalloproteinases plays critical role in TNF-mediated matrix remodeling. Nonethe-
ess, clinical trials (RECOVER, RENAISSANCE, RENEWAL, and
TTACH) using neutralizing antibody against TNF failed to reduce
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.05.014mortality of patients with congestive heart failure [11]. So far,
inhibition of TNF has not been effective for prevention of LV
remodeling and heart failure in humans.
Similar to TNF, FasL activates the extrinsic apoptosis pathway
through binding to Fas that belongs to the death-receptor fam-
ily. Binding of ligands to death-receptor allows complex formation
with FADD (Fas-associated protein with death domain) and intra-
cellular domain of death receptors. The receptor and FADD complex
activates caspase 8 and down-stream caspases. Previous studies
have demonstrated the association of Fas/FasL axis in LV remod-
eling [9,12,13]. In the REVE-2 study, the authors enrolled a large
number of patients with typical ﬁrst anterior myocardial infarc-
tion and failed to show a signiﬁcant association between circulating
soluble FasL and LV remodeling after AMI  [14,15].
There are several possibilities to explain the discrepancy
between previous studies regarding cardiac apoptosis and the
REVE-2 study. (1) Most previous studies were performed in rodent
models. Thus the discrepancy might be caused by species dif-
ference. (2) As indicated by the authors, blood sampling was
performed only once in the REVE-2 study (1 month after AMI).
Different results might be obtained if changes in circulating lev-
els of Fas/FasL were monitored by serial blood sampling after AMI.
(3) Also Fas/FasL pathway (extrinsic pathway) was not involved;
the intrinsic pathway might play a critical role in apoptosis of car-
diac myocytes, because pancaspase inhibitor has attenuated the LV
remodeling [6].
Inﬂammation and matrix remodeling after AMI  consists of com-
plex mechanisms including increased oxidative stress, cytokine
storms, and geometric changes of left ventricle. To date, vari-
ous therapies have been attempted to prevent LV remodeling
such as inhibition of renin–angiotensin–aldosterone system, car-
diac regeneration therapy, gene therapy, and administration
of nitric oxide, natriuretic peptide, and scavengers of reac-
tive oxygen species [16]. Interestingly, the REVE-2 study also
showed that hepatocyte growth factor was  signiﬁcantly associ-
ated with LV remodeling and can be a prognostic biomarker after
AMI  [14,15].
In experimental studies, the percentage of apoptotic cells rela-
tive to total cardiac myocytes is quite small after AMI. The precise
role of apoptosis in LV remodeling after AMI  should be clariﬁed
in humans. In addition to the measurement of circulating biomark-
ers, a novel modality such as molecular imaging is needed to clarify
the role of apoptosis in LV remodeling. Understanding the complex
process of LV remodeling will lead to novel therapeutic approaches
to treat the increasing number of patients with heart failure after
AMI.
vier Ltd. All rights reserved.
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[ig. 1. Signal transduction pathways for apoptosis. Apoptosis is induced by various
nti-cancer drugs, and oxidative stress. There are two major pathways for induct
nduce  the extrinsic pathway, whereas mitochondrial cytochrome C is a major sign
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